GB0917745D0 - Compositions for the prevention or treatment of migraine - Google Patents
Compositions for the prevention or treatment of migraineInfo
- Publication number
- GB0917745D0 GB0917745D0 GBGB0917745.2A GB0917745A GB0917745D0 GB 0917745 D0 GB0917745 D0 GB 0917745D0 GB 0917745 A GB0917745 A GB 0917745A GB 0917745 D0 GB0917745 D0 GB 0917745D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- migraine
- prevention
- compositions
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000019695 Migraine disease Diseases 0.000 title 1
- 206010027599 migraine Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0917745.2A GB0917745D0 (en) | 2009-10-09 | 2009-10-09 | Compositions for the prevention or treatment of migraine |
| PCT/GB2010/001881 WO2011042701A1 (en) | 2009-10-09 | 2010-10-07 | Compositions for the prevention or treatment of migraine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0917745.2A GB0917745D0 (en) | 2009-10-09 | 2009-10-09 | Compositions for the prevention or treatment of migraine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB0917745D0 true GB0917745D0 (en) | 2009-11-25 |
Family
ID=41402816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB0917745.2A Ceased GB0917745D0 (en) | 2009-10-09 | 2009-10-09 | Compositions for the prevention or treatment of migraine |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB0917745D0 (en) |
| WO (1) | WO2011042701A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011163301A1 (en) | 2010-06-25 | 2011-12-29 | Global Healthcare Focus, Llc | Methods of treating optic disorders |
| CA2876169C (en) * | 2011-06-21 | 2023-01-24 | Global Healthcare Focus, Llc | Methods of preventing or treating disease states related to certain metabolic abnormalities |
| US20150209374A1 (en) | 2014-01-29 | 2015-07-30 | Faro Owiesy | Composition and Method for Curing Migraine Headaches |
| WO2018130865A1 (en) * | 2017-01-13 | 2018-07-19 | The Hospital For Sick Children | Pediatric headache treatment and method |
| WO2019000101A1 (en) * | 2017-06-29 | 2019-01-03 | Msi Methylation Sciences Inc. | Novel formulations useful in treating folate deficiencies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3064000A (en) | 1959-04-14 | 1962-11-13 | Sankyo Kabushiki Kaisha | S-benzoylthiamine o-monophosphate and a process for preparing the same |
| US6517832B1 (en) | 2001-08-24 | 2003-02-11 | Jeffrey L. Marrongelle | Formulations and methods for treating chronic migraine |
| US20080206360A1 (en) | 2004-12-01 | 2008-08-28 | Curt Hendrix | Folate based migraine treatment |
| EP2139466B1 (en) * | 2007-03-22 | 2019-10-23 | Neurocentria, Inc. | Magnesium compositions and uses thereof |
-
2009
- 2009-10-09 GB GBGB0917745.2A patent/GB0917745D0/en not_active Ceased
-
2010
- 2010-10-07 WO PCT/GB2010/001881 patent/WO2011042701A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011042701A1 (en) | 2011-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL225471B (en) | Compositions for the prevention and treatment of cancer | |
| EP2440209A4 (en) | Compositions and methods for the prevention and treatment of heart failure | |
| ZA201204625B (en) | Analogues for the treatment or prevention of flavivirus infections | |
| IL210997A0 (en) | Compositions for the treatment of mrsa and uses thereof | |
| IL217503A0 (en) | Benzimidazole analogues for the treatment or prevention of flavivirus infections | |
| GB0802403D0 (en) | Compositions for the treatment of oxidative stress | |
| EP2273880A4 (en) | Novel formulations for treatment of migraine | |
| SI2415763T1 (en) | Pharmaceutical composition for treating or preventing glaucoma | |
| IL251083B (en) | Compounds and compositions for the treatment of cancer | |
| PL2429507T3 (en) | Phosphate-free pharmaceutical composition for the treatment of glaucoma | |
| SI2605764T1 (en) | Compositions for the treatment of cancer | |
| IL214349A0 (en) | Compositions and methods for the treatment of cancer | |
| PL2498603T3 (en) | Use of anti-bacterial agents for the treatment of epithelial-related conditions | |
| IL209360A (en) | Pharmaceutical compositions comprising pm00104 for the treatment of multiple myeloma | |
| PL3081097T3 (en) | Composition for the treatment of infertility | |
| GB0917745D0 (en) | Compositions for the prevention or treatment of migraine | |
| HU0900231D0 (en) | Compositions for the treatment of allergic disorders | |
| IL208624A0 (en) | Compositions for the treatment of lice | |
| EP2459507A4 (en) | Use of erythritol for the prevention or treatment of hypertension | |
| AP2011005893A0 (en) | Thia-triaza-cyclopentazulenes as P13-kinases inhibitors for the treatment of cancer. | |
| GB0808326D0 (en) | Compositions and methods for the treatment of fybromyalgia | |
| GB0921929D0 (en) | Compositions and methods for the treatment of influenza | |
| GB0911577D0 (en) | Compositions for the treatment of dry eye | |
| IL223055A0 (en) | Compositions for the treatment of gynaecological disorders | |
| GB0906210D0 (en) | Compounds for the treatment of flaviviral |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |